Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A new tactic against COVID-19
July/August 2020
SHARING OPTIONS:

TORONTO—FSD Pharma Inc. recently received FDA approval to submit an Investigational New Drug Application for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) as a treatment for COVID-19, the disease caused by the SARS-CoV-2 virus. Patients with severe cases of COVID-19 experience an overreactive inflammatory response that can result in a fatal cytokine storm, and FSD-201 is being advanced for anti-inflammatory properties that could avoid cytokine storms linked to acute lung injury.
 
Dr. Raza Bokhari, executive co-chairman and CEO of FSD Pharma, commented in part that “Numerous studies over the past 40 years also validate the efficacy and safety of ultramicronized PEA in the treatment and prophylactic effects in respiratory infections. These studies also pointed out that the ease of application of PEA offers the possibility to have a quick therapeutic answer ready in case of a flu epidemic.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.